Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: A subset analysis from the MDS-004 study

European Journal of Haematology

Volumn 93, Issue 5, 2014, Pages 429-438

  Giagounidis, Aristoteles ^a   Mufti, Ghulam J ^b   Mittelman, Moshe ^c   Sanz, Guillermo ^d   Platzbecker, Uwe ^e   Muus, Petra ^f   Selleslag, Dominik ^g   Beyne Rauzy, Odile ^h   te Boekhorst, Peter ⁱ   del Cañizo, Consuelo ^j   Guerci Bresler, Agnès ^k   Nilsson, Lars ^l   Lübbert, Michael ^m   Quesnel, Bruno ⁿ   Ganser, Arnold ^o   Bowen, David ^p   Schlegelberger, Brigitte ^o   Göhring, Gudrun ^o   Fu, Tommy ^q   Benettaib, Bouchra ^q   Hellström Lindberg, Eva ^r   Fenaux, Pierre ^s   more..

^a MARIEN HOSPITAL DÜSSELDORF   (Germany)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g General Hospital St Jan   (Belgium)

^h CHU PURPAN   (France)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k CHU NANCY BRABOIS   (France)

^l LUND UNIVERSITY HOSPITAL   (Sweden)

^m UNIVERSITY OF FREIBURG   (Germany)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o HANNOVER MEDICAL SCHOOL   (Germany)

^p ST JAMES S INSTITUTE OF ONCOLOGY   (United Kingdom)

^q CELGENE CORPORATION   (United States)

^r KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^s SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

Acute myeloid leukaemia; Del(5q); Lenalidomide; Myelodysplastic syndromes; Transfusion independence

Indexed keywords

ANTIANEMIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; ANTINEOPLASTIC AGENT; THALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY ANEMIA; RETROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CHROMOSOME 5; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG ADMINISTRATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; RISK; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84911955301     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12380     Document Type: Article

References (15)

1. Bernasconi P, Klersy C, Boni M, et al. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes. Br J Haematol 2007;137:193-205.
2. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385-95.
3. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820-9.
4. Solé F, Luño E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005;90:1168-78.
5. Germing U, Lauseker M, Hildebrandt B, et al. Survival, prognostic factors, and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia 2012;26:1286-92.
6. Le Bras F, Sebert M, Kelaidi C, et al. Treatment by lenalidomide in lower risk myelodysplastic syndrome with 5q deletion-the GFM experience. Leuk Res 2011;35:1444-8.
7. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
8. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
9. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65.
10. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10.
11. Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006;12:5-10.
12. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118:3765-76.
13. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671-4.
14. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
15. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.